



जैव प्रौद्योगिकी विभाग
Department of Biotechnology
Ministry of Science & Technology
Government of India



Confederation of Indian Industry

2nd National Biotechnology Conclave 2018
Driving Inclusive Growth for Indian Bio-economy Vision- 2025
22 November 2018: Jacaranda Hall, India Habitat Centre, New Delhi

INAUGURAL SESSION
22 November 2018; 1000 – 1050 HRS

1000-1005 Hrs	Welcome Address and Moderated by	Dr Mahesh Bhalgat Co-Chairman, CII National Committee on Biotechnology Executive Director and Chief Operating Officer Shantha Biotechnics
1005-1015 Hrs	Address	Dr Rajesh Jain Managing Director Panacea Biotec
1015-1020 Hrs	<i>Release of the Biosimilars Publication</i>	
1020-1030 Hrs	Special Address	Prof Samir K Brahmachari Former Director General Council of Scientific and Industrial Research
1035 -1045 Hrs	Special Address	Dr Alka Sharma Scientist G Department of Biotechnology Ministry of Science & Technology
1045 -1050 Hrs	Concluding Remarks by the Moderator	



2nd National Biotechnology Conclave 2018
Driving Inclusive Growth for Indian Bio-economy Vision- 2025
22 November 2018: Jacaranda Hall, India Habitat Centre, New Delhi

PANEL DISCUSSION I
22 November 2018; 1100 – 1200 HRS

Catalyzing the vaccine industry

Vaccine industry has earned India a special place in the global arena. Indian vaccine companies have excelled at successfully collaborating with global partners ensuring technology access and product development by adopting innovative technologies. However, there still remains a scope of harnessing the full potential of the sector. This panel aims to discuss the key regulatory policies that builds close synergy between regulators; industry and academia that would help achieve the most efficient health benefits from the best in this industry.

1100-1105 Hrs	Opening Remarks by the Moderator	Dr Mahesh Bhargat Co-Chairman, CII National Committee on Biotechnology Executive Director and Chief Operating Officer Shantha Biotechnics
1105-1115 Hrs	Special Address	Dr Alka Sharma Scientist G Department of Biotechnology Ministry of Science & Technology
1115-1150 Hrs	Panelists	Dr Rajesh Jain Chairman, CII National Committee on Biotechnology & Managing Director Panacea Biotec Ltd Dr Suresh Jadhav Executive Director Serum Institute of India Private Limited Dr Anand Kumar Managing Director Indian Immunologicals Limited Dr Nachiket Mor Director- India Office Bill and Melinda Gates Foundation Dr Davinder Gill Chief Executive Officer Hilleman Laboratories
1150-1200 Hrs	Closing Remarks by the Moderator	



2nd National Biotechnology Conclave 2018
Driving Inclusive Growth for Indian Bio-economy Vision- 2025
22 November 2018: Jacaranda Hall, India Habitat Centre, New Delhi

PANEL DISCUSSION II
22 November 2018; 1200 – 1300 HRS

The current state of biosimilars and prospects for the future

India is poised to be the world's largest hub for manufacturing biological drugs. It's been evident for a decade now that biological drugs are the future of medicine. If we are to realize the full potential of biosimilars to improve people's health, it is essential to encourage public policy and regulatory environment to support research and development that drives biosimilar innovation. We need to assess that how ready are we, to both exploit the opportunities biosimilars offer, and derive the benefits of these new and innovative medicines. This panel will discuss the current state of biosimilars and strategize the next 10 years plan to accomplish India's dominant position in regulated and RoW markets.

1200-1205 Hrs	Opening Remarks by the Moderator	Ms Pushpa Vijayraghavan Director Sathguru Management Consultants
1205-1225 Hrs	Special Address	Dr S R Rao Scientist H Department of Biotechnology Minister of Science & Technology
1225-1250 Hrs	Panelists	Dr Anil Koul Director CSIR – IMTech Mr Atin Tomar President CPL Biologicals Pvt. Ltd. Mr Jaspreet Singh Head- Biosimilars Formerly- Intas Pharmaceuticals Ltd. Mr Sunil Thakur Managing Director Quadria Capital
1250-1300 Hrs	Closing Remarks by the Moderator	
1300-1400 Hrs	Networking Lunch	



2nd National Biotechnology Conclave 2018
Driving Inclusive Growth for Indian Bio-economy Vision- 2025
22 November 2018: Jacaranda Hall, India Habitat Centre, New Delhi

PANEL DISCUSSION III
22 November 2018; 1400 – 1500 HRS

Indian bio-agriculture industry as a strategic imperative for future food security

The Indian agriculture sector remains the backbone of the nation's economy, accounting for 15% of the country's GDP. While the central government has taken a few positive steps to promote the bio-agriculture sector, lack of implementation rigor, and existing bottlenecks in the current regulatory framework have impaired the full potential of biotechnologically engineered and genetically modified foods and crops. This Session proposes to address such regulatory shortcomings and political hurdles that may help India become a more competitive economic player and an influential international participant in this rapidly changing field.

1400-1405 Hrs	Opening Remarks by the Moderator	Dr Arvind Kapur Managing Director Acsen HyVeg (P) Ltd.
1405-1445 Hrs	Remarks by the Panelists	Prof Deepak Pental Head Department of Genetics – Delhi University Dr Usha Barwale Zehr Director and Chief Technology Officer Maharashtra Hybrid Seeds Company Private Limited Dr Paresh Verma President and Director - Research Shriram Bioseed Genetics
1450-1500 Hrs	Closing Remarks by the Moderator	



2nd National Biotechnology Conclave 2018
Driving Inclusive Growth for Indian Bio-economy Vision- 2025
22 November 2018: Jacaranda Hall, India Habitat Centre, New Delhi

PANEL DISCUSSION IV
22 November 2018; 1515 – 1615 HRS

Striking gold with the adoption of precision and personalized medicines

It is reported that a significantly rising number of middle-class Indians incur losses of around \$23 billion annually in treating or getting tested for non-communicable diseases. Precision medicine is the most promising economical solution for middle-class Indians. Targeted therapies aim to reduce the costs of hospice stay to markedly reduce overall financial, physical and psychological costs seen with experimental diagnostics treatments. With a projected growth of 25% under the aegis of India's best biotech professionals and diagnosticians, precision medicine is already being practiced in several specialties like oncology, cardiology, psychiatry and diabetology. The purpose of the Session is to brainstorm upon the opportunities and challenges as the Indian healthcare industry transforms towards precision medicine practices.

1515-1520 Hrs	Opening Remarks by the Moderator	Dr B V Ravi Kumar Managing Director Xcyton
1520-1530 Hrs	Special Address	Dr. Anurag Agrawal Director Institute of Genomics and Integrative Biology
1530-1605 Hrs	Panelists	Mr Mahesh Pratapneni Director Medgenome Mr Neeraj Gupta Founder & CEO Imperial Life Sciences Dr Liu Muyun Director and Founder National and Local Joint Engineering Laboratory of Personalized Cell Therapy, Shenzhen Kenuo Medical Laboratory Mr Pranav Anam Founder and CEO The Gene Box Mr Kapil Sood Senior Director- South Asia Thermo Fisher Scientific India Pvt. Ltd.
1605-1615 Hrs	Closing Remarks by the Moderator	



2nd National Biotechnology Conclave 2018
Driving Inclusive Growth for Indian Bio-economy Vision- 2025
22 November 2018: Jacaranda Hall, India Habitat Centre, New Delhi

PANEL DISCUSSION V
22 November 2018; 1615 – 1730 HRS

Building a future ready biotechnology sector in “Make in India” era

Biotechnology is one of the key sectors identified by the government as part of ‘Make in India’, and the National Biotechnology Development Strategy has provided a strategic roadmap for India’s emergence as a global biotech innovation hub with a target of \$100 billion by 2025. This would entail access to adequate capital, quality infrastructure, conducive policy framework and high-end talent if India is to build global leadership as a knowledge economy and a potential investment market with research and innovation as its foundation. The Session would discuss the strategies for fostering the biotech ecosystem in India with convergence of bioentrepreneurship.

1615-1630 Hrs	Opening Remarks by the Moderator	Dr P M Murali Founder Chairman Jananom Private limited
1630-1635 Hrs	Special Address	Dr Shirshendu Mukherjee Mission Director DBT-BIRAC-BMGF-Wellcome Trust
1635-1720 Hrs	Panelists	Dr Prabuddha Kundu Co-founder & Executive Director Premas Biotech Pvt. Ltd Mr BN Manohar Managing Director Stempeutics Research Pvt. Ltd Mr Ranjit Madan Chief Executive Officer Life Sciences Sector Skill Development Council Dr Ramanan Tirumoorthy VP – Technical (R&D Head) Richcore India Dr Taslimarif Saiyed CEO and Director Centre for Cellular and Molecular Platforms
1720 - 1730Hrs	Closing Remarks by the Moderator	
1730 Hrs	Close of the Conclave	